Please login to the form below

Not currently logged in
Email:
Password:

vintafolide

This page shows the latest vintafolide news and features for those working in and with pharma, biotech and healthcare.

Amgen's trebananib misses survival target in ovarian cancer

Amgen's trebananib misses survival target in ovarian cancer

Other candidates coming through the pipeline include Boehringer Ingelheim's triple angiokinase inhibitor nintedanib, Merck &Co's anti-folate drug vintafolide, AstraZeneca's PARP inhibitor olaparib and Array BioPharma/Novartis's

Latest news

  • Merck's vintafolide fails ovarian cancer trial Merck's vintafolide fails ovarian cancer trial

    PROCEED compared the combination of vintafolide and pegylated liposomal doxorubicin to a combination of doxorubicin and placebo. ... Merck licensed rights to vintafolide in 2012 in a deal valued at up to $1bn, including $120m upfront.

  • EMA backs Janssen rare disease drug for approval EMA backs Janssen rare disease drug for approval

    it. Staying in the orphan disease area the CHMP also gave the nod to Endocyte's Vynfinit (vintafolide), a treatment for platinum-resistant ovarian cancer, along with two companion diagnostic drugs

  • Boehringer/Lilly's empagliflozin among CHMP recommendations Boehringer/Lilly's empagliflozin among CHMP recommendations

    There were also recommendations for four orphan drugs: Janssen-Cilag's Sylvant (situximab) and, along with the companion diagnostic drugs Folcepri (etarfolatide) and Neocepri (folic acid), Endocyte's Vynfinit (vintafolide).

  • Late-stage ovarian cancer Late-stage ovarian cancer

    Endocyte's vintafolide is a folate-targeted conjugate composed of a folate molecule plus a vinca alkaloid, which acts as a microtubule destabilising agent. ... Vintafolide targets and enters cancer cells via the folate vitamin receptor, which is

  • Merck's vintafolide shows its worth in ovarian cancer Merck's vintafolide shows its worth in ovarian cancer

    Phase II data shows improvement on current oncology treatments. Merck &Co's cancer drug candidate vintafolide has improved on standard treatment for women with ovarian cancer, according to newly-published phase ... Vintafolide is a small molecule drug

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics